GT Biopharma Inc GTBP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 11:55 AM EST
4.64quote price arrow down-0.35 (-7.01%)
Volume
97,418
52 week range
1.45 - 13.09

...

Loading . . .

KEY STATS

  • Open5.11
  • Day High5.11
  • Day Low4.55
  • Prev Close4.99
  • 52 Week High13.09
  • 52 Week High Date12/24/20
  • 52 Week Low1.45
  • 52 Week Low Date03/05/20
  • Market Cap118.69M
  • Shares Out25.58M
  • 10 Day Average Volume0.45M
  • Dividend-
  • Dividend Yield-
  • Beta-0.14
  • 1 Year % Change173.53

RATIOS/PROFITABILITY

  • EPS (TTM)-3.42
  • P/E (TTM)-1.36
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-5.445M
  • ROE (MRQ)-193.69%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-77.79%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest GT Biopharma Inc News

There is no recent news for this security.

Latest GTBP News From Our Partners

QUOTE FINDER

Profile

MORE
GT Biopharma, Inc., formerly OXIS International, Inc., is an immuno-oncology company. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. The Company develops drugs focused on the treatment of cancer. Its technology platform consists of bispecific and trispecific single-chain variable fragment (scFv) constructs, full-length antibodies, drug payloads, antibody-drug linkers, dual-drug payload...
Anthony Cataldo
Chairman
Steven Weldon CPA
Chief Financial Officer
Michael Handelman CPA
Chief Financial Officer
Address
9350 WILSHIRE BLVD., SUITE 203
Beverly Hills, CA
90212
United States